The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells
Abstract
Background CD33 (Siglec‐3) is becoming increasingly important as a target of antibody‐mediated therapy in acute myeloid leukaemia (AML). In normal myelopoiesis, expression of CD33 is restricted to advanced stages of differentiation, whereas primitive stem cells do not express CD33. In the present study, we asked whether leukaemic stem cells in patients with AML express CD33. Materials and methods A multicolour‐staining technique was applied in 11 patients with AML, and leukaemic progenitors defined as CD34+/CD38−/CD123+ cells. AML stem cells were purified by cell sorting and were examined for expression of CD33 mRNA by reverse transcriptase–polymerase chain reaction (RT–PCR). Results In all patients in whom the majority of myeloblasts expressed CD33 (n = 8), AML progenitors reacted with the CD33 antibody P67·6. Repopulation experiments utilizing irradiated NOD/SCID mice confirmed that AML stem cells in these patients reside within the CD33+ subpopulation of the leukaemic clone. Moreover, highly purified AML stem cells (> 98% purity) from patients with CD33+ AML were found to express CD33 mRNA in RT–PCR analyses. CD33 was neither detectable on CD34+/CD38− cells in normal bone marrow nor on leukaemic stem cells in patients with CD33‐negative AML. Conclusions Leukaemic stem cells in patients with CD33+ AML express CD33. This observation is in favour of novel treatment concepts employing CD33‐targeting antibodies in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blair, A., Hogge, D. E., Ailles, L. E., Lansdorp, P. M., & Sutherland, H. J. (1997) · Blood · doi:10.1182/blood.v89.9.3104 · Cited by 335
Blair, A., & Sutherland, H. J. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00155-7 · Cited by 165
Cited by
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Jin, L., Lee, E. M., Ramshaw, H. S., Busfield, S. J., Peoppl, A. G., Wilkinson, L., Guthridge, M. A., Thomas, D., Barry, E. F., Boyd, A., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.04.018 · Cited by 522
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Kikushige, Y., Shima, T., Takayanagi, S.-I., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T., Inagaki, Y., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.014 · Cited by 477
Wang, Q.-S., Wang, Y., Lv, H.-Y., Han, Q.-W., Fan, H., Guo, B., Wang, L.-L., & Han, W.-D. (2015) · Molecular Therapy · doi:10.1038/mt.2014.164 · Cited by 418
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhäuser, M., von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.39 · Cited by 355
Metadata
- Authors
- Hauswirth, A. W., Florian, S., Printz, D., Sotlar, K., Krauth, M. ‐., Fritsch, G., Schernthaner, G. ‐., Wacheck, V., Selzer, E., Sperr, W. R., & Valent, P.
- Venue
- European Journal of Clinical Investigation
- Publisher
- Wiley
- Published
- 2006-12-06
- Volume
- 37
- Issue
- 1
- Pages
- 73-82
- ISSN
- 0014-2972 (ISSN-L)
- 1365-2362
- OpenAlex
- W1990564763
- Cited by
- 158
- References
- 2
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells. https://app.cochat.ai/papers/10.1111/j.1365-2362.2007.01746.x
- The paper
- Hauswirth, A. W., Florian, S., Printz, D., Sotlar, K., Krauth, M. ‐., Fritsch, G., Schernthaner, G. ‐., Wacheck, V., Selzer, E., Sperr, W. R., & Valent, P. (2007). Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2007.01746.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.